Literature DB >> 22410319

Streptavidin suppresses T cell activation and inhibits IL-2 production and CD25 expression.

Kentaro Yomogida1, Yuan Chou, Jonathan Pang, Bobby Baravati, Brian J Maniaci, Shili Wu, Yong Zhu, Cong-Qiu Chu.   

Abstract

Streptavidin is widely used as a detection tool in biology research because of its high affinity and specificity binding to biotin. Biotin-streptavidin system has also been explored for detection of infection and tumor in clinical medicine. Here, we show immunosuppressive property of streptavidin on T cell activation and proliferation. Upon CD3 and CD28 stimulation, CD4(+) T cells produce interleukin 2 (IL-2) and express IL-2 receptor α chain (CD25). Addition of streptavidin in T cell culture suppressed IL-2 synthesis and CD25 expression with no cytotoxicity. The immunosuppressive effect of streptavidin was reversed by excessive biotin. Conjugated to a single chain anti-CD7 variable fragment (scFvCD7), streptavidin was directly delivered to T cells and showed substantially more profound suppressive effect on T cell activation. These results suggest that streptavidin could potentially be used as a novel immunomodulator. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22410319      PMCID: PMC3340517          DOI: 10.1016/j.cyto.2012.02.007

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  46 in total

1.  Biotinylation is a natural, albeit rare, modification of human histones.

Authors:  Toshinobu Kuroishi; Luisa Rios-Avila; Valerie Pestinger; Subhashinee S K Wijeratne; Janos Zempleni
Journal:  Mol Genet Metab       Date:  2011-09-03       Impact factor: 4.797

2.  Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication.

Authors:  H P Kalofonos; M Rusckowski; D A Siebecker; G B Sivolapenko; D Snook; J P Lavender; A A Epenetos; D J Hnatowich
Journal:  J Nucl Med       Date:  1990-11       Impact factor: 10.057

3.  Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin.

Authors:  A E Frankel; J H Laver; M C Willingham; L J Burns; J H Kersey; D A Vallera
Journal:  Leuk Lymphoma       Date:  1997-07

4.  Induction of apoptosis following antigen presentation by T cells: anergy and apoptosis are two separate phenomena.

Authors:  R G Hargreaves; N J Borthwick; M S Gilardini Montani; M S Montani; E Piccolella; P Carmichael; R I Lechler; A N Akbar; G Lombardi
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

5.  FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin.

Authors:  J J Siekierka; M J Staruch; S H Hung; N H Sigal
Journal:  J Immunol       Date:  1989-09-01       Impact factor: 5.422

6.  Studies on the biotin-binding sites of avidin and streptavidin. A chemically induced dynamic nuclear polarization investigation of the status of tyrosine residues.

Authors:  G Gitlin; I Khait; E A Bayer; M Wilchek; K A Muszkat
Journal:  Biochem J       Date:  1989-04-15       Impact factor: 3.857

7.  Streptavidin--a substance with avidin-like properties produced by microorganisms.

Authors:  F Tausig; F J Wolf
Journal:  Biochem Biophys Res Commun       Date:  1964       Impact factor: 3.575

8.  Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection.

Authors:  A I Lazarovits; J Rochon; L Banks; D J Hollomby; N Muirhead; A M Jevnikar; M J White; P L Amlot; L Beauregard-Zollinger; C R Stiller
Journal:  J Immunol       Date:  1993-06-01       Impact factor: 5.422

9.  Cyclophilin: a specific cytosolic binding protein for cyclosporin A.

Authors:  R E Handschumacher; M W Harding; J Rice; R J Drugge; D W Speicher
Journal:  Science       Date:  1984-11-02       Impact factor: 47.728

10.  Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.

Authors:  Andres Forero; Paul L Weiden; Julie M Vose; Susan J Knox; Albert F LoBuglio; Jordan Hankins; Michael L Goris; Vincent J Picozzi; Don B Axworthy; Hazel B Breitz; Robert B Sims; Richard G Ghalie; Sui Shen; Ruby F Meredith
Journal:  Blood       Date:  2004-03-02       Impact factor: 22.113

View more
  5 in total

1.  Artificial T Cell Mimetics to Combat Melanoma Tumor Growth.

Authors:  Shilpaa Mukundan; Dongli Guan; Amy Singleton; Yunlong Yang; Matthew Li; Biju Parekkadan
Journal:  Am J Adv Drug Deliv       Date:  2018

2.  Cell penetrating recombinant Foxp3 protein enhances Treg function and ameliorates arthritis.

Authors:  Kentaro Yomogida; Shili Wu; Bobby Baravati; Camilo Avendano; Tom Caldwell; Brian Maniaci; Yong Zhu; Cong-Qiu Chu
Journal:  Biochem Biophys Res Commun       Date:  2013-03-26       Impact factor: 3.575

3.  CD4 aptamer-RORγt shRNA chimera inhibits IL-17 synthesis by human CD4(+) T cells.

Authors:  Pingfang Song; Yuan K Chou; Xiaowei Zhang; Roberto Meza-Romero; Kentaro Yomogida; Gil Benedek; Cong-Qiu Chu
Journal:  Biochem Biophys Res Commun       Date:  2014-09-18       Impact factor: 3.575

4.  Support vector machine classification of streptavidin-binding aptamers.

Authors:  Xinliang Yu; Yixiong Yu; Qun Zeng
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

5.  Highly tailorable gellan gum nanoparticles as a platform for the development of T cell activator systems.

Authors:  Daniel B Rodrigues; Helena R Moreira; Mariana T Cerqueira; Alexandra P Marques; António G Castro; Rui L Reis; Rogério P Pirraco
Journal:  Biomater Res       Date:  2022-09-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.